Description
Background:
Zenocutuzumab is antibody dependent cellular cytotoxicityPenhanced bispecific antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zenocutuzumab docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It is being evaluated in phase II clinical trials for patients (pts) with NRG1+ cancer. Since it targets HER2 and HER3 simultaneously, Zenocutuzumab is a novel therapeutic paradigm for patients with NRG1 fusion positive cancers.
Intended Use:
For Estimation of Zenocutuzumab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!